(NASDAQ: BNTC) Benitec Biopharma's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 45.14%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.81%.
Benitec Biopharma's earnings in 2025 is -$41,823,000.On average, 10 Wall Street analysts forecast BNTC's earnings for 2026 to be -$38,972,036, with the lowest BNTC earnings forecast at -$61,060,366, and the highest BNTC earnings forecast at -$32,710,910. On average, 9 Wall Street analysts forecast BNTC's earnings for 2027 to be -$47,579,814, with the lowest BNTC earnings forecast at -$69,024,761, and the highest BNTC earnings forecast at -$36,977,551.
In 2028, BNTC is forecast to generate -$37,045,275 in earnings, with the lowest earnings forecast at -$51,436,721 and the highest earnings forecast at -$12,088,815.